The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Incomplete Peripheral CD4+Cell Count Restoration in HIV‐Infected Patients Receiving Long‐Term Antiretroviral Treatment
Open accessAbstract
BACKGROUND: Although antiretroviral therapy has the ability to fully restore a normal CD4(+) cell count (>500 cells/mm(3)) in most patients, it is not yet clear whether all patients can achieve normalization of their CD4(+) cell count, in part because no study has followed up patients for >7 years. METHODS: Three hundred sixty-six patients from 5 clinical cohorts who maintained a plasma human immunodeficiency virus (HIV) RNA level 1000 copies/mL for at least 4 years after initiation of antiretroviral therapy were included. Changes in CD4(+) cell count were evaluated using mixed-effects modeling, spline-smoothing regression, and Kaplan-Meier techniques. RESULTS: The majority (83%) of the patients were men. The median CD4(+) cell count at the time of therapy initiation was 201 cells/mm(3) (interquartile range, 72-344 cells/mm(3)), and the median age was 47 years. The median follow-up period was 7.5 years (interquartile range, 5.5-9.7 years). CD4(+) cell counts continued to increase throughout the follow-up period, albeit slowly after year 4. Although almost all patients (95%) who started therapy with a CD4(+) cell count 300 cells/mm(3) were able to attain a CD4(+) cell count 500 cells/mm(3), 44% of patients who started therapy with a CD4(+) cell count <100 cells/mm(3) and 25% of patients who started therapy with a CD4(+) cell count of 100-200 cells/mm(3) were unable to achieve a CD4(+) cell count >500 cells/mm(3) over a mean duration of follow-up of 7.5 years; many did not reach this threshold by year 10. Twenty-four percent of individuals with a CD4(+) cell count <500 cells/mm(3) at year 4 had evidence of a CD4(+) cell count plateau after year 4. The frequency of detectable viremia ("blips") after year 4 was not associated with the magnitude of the CD4(+) cell count change. CONCLUSIONS: A substantial proportion of patients who delay therapy until their CD4(+) cell count decreases to <200 cells/mm(3) do not achieve a normal CD4(+) cell count, even after a decade of otherwise effective antiretroviral therapy. Although the majority of patients have evidence of slow increases in their CD4(+) cell count over time, many do not. These individuals may have an elevated risk of non-AIDS-related morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, S., Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., et al. (2006) · Nature Medicine · doi:10.1038/nm1511 · Cited by 3,559
Self-citationCD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study
(2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1632 · Cited by 1,113
Hunt, P. W., Martin, J. N., Sinclair, E., Bredt, B., Hagos, E., Lampiris, H., & Deeks, S. G. (2003) · The Journal of Infectious Diseases · doi:10.1086/374786 · Cited by 852
Self-citationDeeks, S. G., Kitchen, C. M. R., Liu, L., Guo, H., Gascon, R., Narváez, A. B., Hunt, P., Martin, J. N., Kahn, J. O., Levy, J., et al. (2004) · Blood · doi:10.1182/blood-2003-09-3333 · Cited by 804
Self-citationPakker, N. G., Notermans, D. W., De Boer, R. J., Roos, M. T. L., Wolf, F. D., Hill, A., Leonard, J. M., Danner, S. A., Miedema, F., & Schellekens, P. T. A. (1998) · Nature Medicine · doi:10.1038/nm0298-208 · Cited by 701
Moore, R. D., & Keruly, J. C. (2007) · Clinical Infectious Diseases · doi:10.1086/510746 · Cited by 415
Kaufmann, G. R. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.18.2187 · Cited by 409
Lewden, C., Chêne, G., Morlat, P., Raffi, F., Dupon, M., Dellamonica, P., Pellegrin, J.-L., Katlama, C., Dabis, F., & Leport, C. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318134257a · Cited by 402
Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART
Nettles, R. E. (2005) · JAMA · doi:10.1001/jama.293.7.817 · Cited by 395
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
Baker, J. V., Peng, G., Rapkin, J., Abrams, D. I., Silverberg, M. J., MacArthur, R. D., Cavert, W. P., Henry, W. K., & Neaton, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cb76 · Cited by 372
ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia
Maldarelli, F., Palmer, S., King, M. S., Wiegand, A., Polis, M. A., Mican, J., Kovacs, J. A., Davey, R. T., Rock-Kress, D., Dewar, R., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030046 · Cited by 333
Bucy, R. P., Hockett, R. D., Derdeyn, C. A., Saag, M. S., Squires, K., Sillers, M., Mitsuyasu, R. T., & Kilby, J. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5863 · Cited by 329
Self-citationKaufmann, G. R., Furrer, H., Ledergerber, B., Perrin, L., Opravil, M., Vernazza, P., Cavassini, M., Bernasconi, E., Rickenbach, M., Hirschel, B., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/431484 · Cited by 313
Hunt, P. W., Deeks, S. G., Rodriguez, B., Valdez, H., Shade, S. B., Abrams, D. I., Kitahata, M. M., Krone, M., Neilands, T. B., Brand, R. J., et al. (2003) · AIDS · doi:10.1097/00002030-200309050-00009 · Cited by 273
Self-citationMocroft, A., Phillips, A., Gatell, J., Ledergerber, B., Fisher, M., Clumeck, N., Losso, M., Lazzarin, A., Fatkenheuer, G., & Lundgren, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60948-9 · Cited by 259
Immunological recovery and antiretroviral therapy in HIV-1 infection
Battegay, M., Nüesch, R., Hirschel, B., & Kaufmann, G. R. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70463-7 · Cited by 255
Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function
Teixeira, L., Valdez, H., McCune, J. M., Koup, R. A., Badley, A. D., Hellerstein, M. K., Napolitano, L. A., Douek, D. C., Mbisa, G., Deeks, S., et al. (2001) · AIDS · doi:10.1097/00002030-200109280-00002 · Cited by 249
Self-citationLiu, Z., Cumberland, W. G., Hultin, L. E., Kaplan, A. H., Detels, R., & Giorgi, J. V. (1998) · Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology · doi:10.1097/00042560-199808010-00004 · Cited by 237
Valdez, H., Connick, E., Smith, K. Y., Lederman, M. M., Bosch, R. J., Kim, R. S., St. Clair, M., Kuritzkes, D. R., Kessler, H., Fox, L., et al. (2002) · AIDS · doi:10.1097/00002030-200209270-00002 · Cited by 211
Garc??a, F., de Lazzari, E., Plana, M., Castro, P., Mestre, G., Nomdedeu, M., Fumero, E., Mart??nez, E., Mallolas, J., Blanco, J. L., et al. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200406010-00007 · Cited by 193
(2009) · PsycEXTRA Dataset · doi:10.1037/e566842010-001 · Cited by 165
Havlir, D. V., Strain, M. C., Clerici, M., Ignacio, C. C., Trabattoni, D., Ferrante, P., & Wong, J. K. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11212-11219.2003 · Cited by 150
Tarwater, P. M., Margolick, J. B., Jin, J., Phair, J. P., Detels, R., Rinaldo, C. R., Giorgi, J. V., & Muñoz, A. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200106010-00012 · Cited by 115
Marziali, M., Santis, W. D., Carello, R., Leti, W., Esposito, A., Isgrò, A., Fimiani, C., Sirianni, M. C., Mezzaroma, I., & Aiuti, F. (2006) · AIDS · doi:10.1097/01.aids.0000247588.69438.fd · Cited by 114
THIERS, B. H. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70447-7 · Cited by 74
Braitstein, P. K. A., Brinkhof, M. W. G., Dabis, F., Schechter, M., Boulle, A., Miotti, P., Wood, R., Laurent, C., Sprinz, E., Seyler, C., et al. (2006) · Open Access CRIS of the University of Bern · doi:10.7892/boris.20071 · Cited by 72
Ostrowski, S. R., Katzenstein, T. L., Thim, P. T., Pedersen, B. K., Gerstoft, J., & Ullum, H. (2005) · The Journal of Infectious Diseases · doi:10.1086/427340 · Cited by 71
Benito, J. M., López, M., Lozano, S., González‐Lahoz, J., & Soriano, V. (2008) · The Journal of Infectious Diseases · doi:10.1086/592716 · Cited by 60
Moore, D. M., Hogg, R. S., Chan, K., TYNDALL, M. W., Yip, B., & Montaner, J. S. (2006) · AIDS · doi:10.1097/01.aids.0000196180.11293.9a · Cited by 56
Cited by
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Self-citationDeeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 644
Self-citationPathogenic Mechanisms of HIV Disease
Moir, S., Chun, T.-W., & Fauci, A. S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130254 · Cited by 463
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Self-citationImmune activation and HIV persistence: implications for curative approaches to HIV infection
Klatt, N. R., Chomont, N., Douek, D. C., & Deeks, S. G. (2013) · Immunological Reviews · doi:10.1111/imr.12065 · Cited by 435
Self-citation
Metadata
- Authors
- Kelley, C. F., Kitchen, C. M. R., Hunt, P. W., Rodriguez, B., Hecht, F. M., Kitahata, M., Crane, H. M., Willig, J., Mugavero, M., Saag, M., Martin, J. N., & Deeks, S. G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-15
- Volume
- 48
- Issue
- 6
- Pages
- 787-794
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2135994316
- Cited by
- 407
- References
- 32
- FWCI
- 11.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.